Tests to quantify fecal levels of chymotrypsin like elastase family member 3 (CELA3 or elastase-1) in feces are widely used to identify patients with exocrine pancreatic insufficiency (EPI). However, the diagnostic accuracy of this test, an ELISA, is not clear. We performed a systematic review and meta-analysis to determine the accuracy of measurement of fecal elastase-1 in detection of EPI.
P rogressive depletion of pancreatic acinar cells leads to exocrine pancreatic insufficiency (EPI), defined as an insufficient amount of pancreatic enzymes resulting in fat malabsorption. 1 Steatorrhea generally does not occur until lipase secretion is reduced by >90%.
2 Because EPI is a frequent cause of diarrhea of obscure origin 3 and can be effectively treated with enzyme supplementation, the ability to accurately diagnose EPI is critical.
Although direct hormone-stimulated pancreas function tests remain the gold standard for the assessment of exocrine function of pancreas, these tests involve patient discomfort, cumbersome equipment, complication risks, nonstandardized test protocols, and are not widely available. 4 Testing can be uncomfortable for patients because of placement of a Dreiling tube through the mouth, intravenous administration of secretin or cholecystokinin, and periodic collection of pancreatic secretions from duodenum. A simplified version of this test called endoscopic secretin pancreatic function test has been developed but its diagnostic utility for EPI has not been proven. 5, 6 Clinicians frequently use empiric trial of pancreatic enzyme replacement and use patient-reported reduction in steatorrhea to establish EPI diagnosis. 7 However, this is not ideal because of availability of different formulations of enzyme replacement, cost of medications, and patient compliance. For these reasons, identification of accurate, noninvasive biomarkers of disease activity is a priority.
Noninvasive (tubeless) pancreatic function tests include fecal chymotrypsin or elastase assays, 72-hour fecal fat, bentiromide (NBT-PABA), or fluorescein dilaurate testing. 8, 9 Fecal chymotrypsin assays are limited in that chymotrypsin is prone to proteolytic degradation and the assay cannot differentiate the exogenous chymotrypsin found in pancreatic enzyme supplements. 10 Quantitative (72-hour) fecal fat estimation is considered the gold standard among the indirect pancreatic function tests. 11, 12 However, this test measures global fat malabsorption (which includes EPI), is cumbersome, and is generally not well tolerated by patients.
Pancreatic elastase-1 is highly stable throughout the intestinal tract because of a lack of relevant proteolytic degradation. 13 The fecal elastase-1 (FE-1) assay is an enzyme-linked immunosorbent assay that specifically measures pancreatic elastase-1, providing the opportunity to assess pancreatic function even in the presence of simultaneous enzyme supplementation. A recent population-based study in Norway reported prevalence of EPI as 11.5% among 914 participants; EPI was defined by FE-1 level <200 mg/g.
14 In another clinic-based study from England, the prevalence of EPI diagnosed also by low FE-1 (<200 mg/g) in 314 patients with chronic diarrhea who satisfied the Rome II criteria for diarrhea-dominant irritable bowel syndrome was 6.1%. 15 Furthermore, EPI prevalence of 4.4% (diagnosed by FE-1 <200 mg/g) was documented in 90 patients who had serologic and histologic evidence of celiac disease in Slovenia; interestingly, the pancreas appeared normal on magnetic resonance imaging in all patients diagnosed with EPI in this study. 16 EPI was diagnosed (based on FE-1 <200 mg/g) in 15% of asymptomatic recovered alcoholics in a prospective study from Brazil. 17 Therefore, EPI is likely to be common, and FE-1 may be an appropriate screening test.
The commercially available enzyme-linked immunosorbent assay kit uses 2 specific monoclonal antibodies against human elastase-1 to apply on a spot fecal sample. 18, 19 Immunoassay for FE-1 is relatively inexpensive, requires <1 g of stool, and is covered by most commercial insurance carriers. 8 The assay is not affected by diet or fasting status. Collected sample is stable for up to 14 days if kept refrigerated. Sample should not be watery or diluted. However, FE-1 tests are known to have assay variability, which could influence the accuracy of the test. 20, 21 Despite the widespread use of FE-1 in screening for EPI, the diagnostic accuracy of FE-1 is not clear.
We aimed to determine the diagnostic accuracy of FE-1 in detecting patients with EPI, and to evaluate effectiveness of FE-1 in differentiating mild, moderate, and severe EPI. Our secondary aim was to evaluate diagnostic accuracy in clinically relevant subgroups.
Methods

Search Strategy
We searched PubMed and Embase from inception through November 2016 for relevant studies using a combination of MeSH terms and keywords according to PRISMA guidelines. 22 The [tiab] ). We did not use any search restrictions. Two authors (R.R.V. and S.S.) independently screened studies for possible inclusion in the review by reading the titles and abstracts. We retrieved the full text of the references that seemed to satisfy our protocol inclusion criteria. We limited studies to English but considered studies in other languages if an English abstract was provided, sufficient data were provided, and met inclusion criteria. Two authors reviewed abstracts and full text of the publication and excluded nonrelevant studies. All disagreements in the screening and reviewing process were discussed and reviewed by a third author (A.T.). Eligible studies published as abstracts only were included only if they met inclusion criteria and sufficient data were available for analysis.
Types of Studies and Participants
We included studies (randomized clinical trials, cohort, case-control, or cross-sectional studies) that evaluated the diagnostic accuracy of FE-1 for the assessment of EPI. Study participants could have been pediatric or adult patients with EPI confirmed with secretin-cerulein test (SCT) or quantitative (72-hour or 24-hour) fecal fat estimation. Studies had to include a control group of patients (healthy or nonpancreatic disease controls) with normal pancreatic function. Studies needed to compare FE-1 results against either SCT or quantitative fecal fat analysis as the reference standards. A normal SCT was defined as fluid secretion >67 mL/30 min, bicarbonate concentration >70 mol/L, bicarbonate output >6.5 mol/30 min after secretin administration, and amylase output >12,000 U/30 min and lipase output >21,000 U/30 min after cerulean administration. 23 Exocrine pancreatic function was evaluated as normal or abnormal according to the result of the SCT. Those with abnormal SCT, quantitative fat estimation was performed only in some studies (Table 1) to further stratify EPI into mild, moderate, and severe as described previously. This meant studies that performed SCT did not need to have quantitative fecal fat test or vice versa. There were only 6 studies in the meta-analysis that compared FE-1 with quantitative fecal fat estimation. Therefore, we separated the studies based on comparison of FE-1 with SCT or FE-1 with quantitative fecal fat estimation.
Mild EPI was defined as reduced output of 1 or more enzymes, bicarbonate concentration and fecal fat excretion normal, moderate EPI as reduced enzyme output and bicarbonate concentration, fecal fat excretion normal, and severe EPI as reduced enzyme output and bicarbonate concentration plus steatorrhea. In the 72-hour fecal fat analysis, steatorrhea was defined as >7 g fat excretion per day using the Va de Kamer method.
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Data Extraction and Management
Two authors (R.R.V. and S.S.) independently extracted data for all included studies (title, journal, year, publication status, and study design); number of participants included; baseline characteristics (adult or pediatric, average age, etiology of EPI); the reference standard test used (secretin stimulation test or quantitative fecal fat); features of FE-1 and reference standard tests (including cutoff values and methods of collection); and the number of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN). We excluded from analysis studies that did not provide sufficient data to determine TP, TN, FP, and FN.
Quality Assessment
We used the Quality Assessment of Diagnostic Accuracy Studies tool to assess the risk of bias in 4 domains regarding participant selection, index test, target condition, reference standard, and flow and timing. 24 Two authors (R.R.V. and S.S.) independently assessed the risk of bias of the included studies. In case of disagreement, we resolved by discussion with a third author (A.T.).
Statistical Analyses
We performed 2 separate analyses. The first model pooled studies using the secretin stimulation test as the reference test, and the second model pooled studies using quantitative stool fat as the reference test. For each, we determined sensitivity, specificity, and positive and negative likelihood ratios (LRþ and LR-) with their 95% confidence intervals (CI). In general, LRþ >10 indicates that the test has large effect on increasing the probability of the disease, LRþ between 5 and 10 indicates a moderate effect on increasing the probability of the disease, and LRþ <5 indicates that the test has a small effect on increasing the probability of the disease. For LR-, test value <0.1 indicates that the test has large effect on decreasing the probability of the disease, test value between 0.5 and 0.1 indicates a moderate effect on decreasing the probability of the disease, and LR->0. 5 indicates that the test has a small effect on decreasing the probability of the disease. We also displayed sensitivity and specificity data in forest plots, and graphed studyspecific estimates of sensitivity and specificity with 95% CI, in the receiver operating characteristic space. A bivariate diagnostic meta-analysis with random effects was used to pool estimates for sensitivity and specificity. We assessed the usefulness of FE-1 in clinical practice by using FP and FN rates. We assessed between-study heterogeneity using the I 2 statistic. We performed several post hoc sensitivity analysis that included (1) the studies of adults only comparing FE-1 with secretin stimulation test, (2) the studies that have chronic pancreatitis (CP) only as the cause of EPI, (3) only studies that used FE-1 200 mg/g as cutoff, and (4) excluding abstracts.
Using the logit transformations for sensitivity and specificity, we also performed graphics to assess aspects of data and identify outliers with scatter plot and chi-square plot. Finally, we performed Deeks funnel plot asymmetry test to investigate potential for publication bias by visual inspection of the patterns drawn from study data, where lack of symmetry should denote high risk of reporting bias. All statistical analyses were performed using STATA version 13.1 (College Station, TX).
Results
Results of the Search
We identified a total of 616 studies (Figure 1 ), of which, only 20 studies (19 papers and 1 abstract) that were published fulfilled the inclusion criteria and were included in the review (Tables 1 and 2 ). All 20 studies were observational. A total of 8 different countries were represented. Nine studies evaluated adults only, 10 studies evaluated both adults and children, and 1 study evaluated children only. In FE-1 versus secretin stimulation test analysis of 14 studies, data on 1101 patients were assessed (428 with EPI and 673 control subjects who were either patients with other gastrointestinal illness [n ¼ 247] or healthy volunteers [n ¼ 426]). Likewise, in FE-1 versus quantitative fecal fat estimation analysis of 6 studies, data on 657 patients were assessed (345 with EPI and 312 control subjects who were either patients with other gastrointestinal illness [n ¼ 122] or healthy volunteers [n ¼ 190] ). The severity of EPI based on secretin stimulation test was reported in 9 studies for mild, 7 for moderate, and 10 studies for severe EPI. The most common causes of EPI were CP (61.9%) and cystic fibrosis (CF) (28.5%). In 18 studies, cutoff point for FE-1 was identified as 200 mg/g. In 2 studies, cut-off points of 175 mg/g and 218 mg/g were identified for FE-1. Figure 2 ). The pooled positive and negative LRs were 6.1 (95% CI, 3.0-12.4) and 0.27 (95% CI, 0.13-0.54) and the diagnostic odds ratio was 23 (95% CI, 6-84), respectively. The TP/TN/FP/FN of FE-1 reported by all studies included in our meta-analysis are presented in Supplementary There was considerable increase in sensitivity and negative LR as EPI severity increased. From 9 studies, patients with mild EPI were pooled and analyzed for diagnostic accuracy of FE-1 (Supplementary Table 2 ). The pooled sensitivity and specificity estimates were 0.49 (95% CI, 0.29-0.70) and 0.92 (95% CI, 0.85-0.96), respectively. The pooled positive and negative LRs were 6.4 (95% CI, 3.0-13.46) and 0.54 (95% CI, 0.35-0.83), respectively.
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Seven studies that had patients with moderate EPI were analyzed for diagnostic accuracy of FE-1 (Supplementary Table 3 ). The pooled sensitivity and Based on the estimates of prevalence of EPI from recent population-based studies, we illustrate the clinical utility of FE-1 in the context of evaluating symptoms in patients with suspected EPI using FP and FN rates. If the prevalence of EPI in patients meeting criteria for irritable bowel syndrome with diarrhea or chronic diarrhea is 5%, then based on our pooled sensitivity and specificity estimates, an abnormal FE-1 test (<200 mg/g) would result in FP rate of 11%, and TP rate of 3.8%. This may result in overprescription of Pancreatic Enzyme Replacement Therapy (PERT) because FP/TP rate is 3:1; but when the test is normal (FE-1 >200 mg/g), then FN rate is 1.1%, which is acceptable in ruling out EPI in this population. In contrast, in a high-prevalence population, such as chronic diarrhea in patients with CP or CF with suspected EPI prevalence of 40%, an abnormal FE-1 test (<200 mg/g) would result in FP rate of 7.2% and TP rate of 30.8%; however, for a normal test (FE-1 >200 mg/g) FN rate is 9.2%. In this situation, a trial of PERT may be reasonable.
Diagnostic Accuracy of Fecal Elastase-1 Versus Quantitative Fecal Fat Estimate
In 6 studies that compared FE-1 with quantitative fecal fat estimate, data on 657 patients were assessed (345 with EPI and 312 control subjects who were either patients with other gastrointestinal illness [n ¼ 122] or healthy volunteers [n ¼ 190] ). The pooled sensitivity and specificity estimates were 0.96 (95% CI, 0.79-0.99) and 0.88 (95% CI, 0.59-0.97), respectively (Supplementary Table 5 ). The TP/TN/FP/FN of FE-1 reported by all studies included in our meta-analysis are presented in Supplementary Table 6 . The pooled positive and negative LRs were 8.4 (95% CI, 1.8-38.1 and 0.04 (95% CI, 0.006-0.29), respectively. These results were similar, with sensitivity of 0.98 (95% CI, 0.82-0.99) and specificity of 0.84 (95% CI, 0.48-0.97), when the study by Symersky et al, 25 which used FE-1 cutoff 218 mg/g, was excluded from the pooled analysis. Diagnostic accuracy of FE-1 versus quantitative fecal fat estimate for mild, moderate, and severe EPI could not be performed because some of the original included studies did not stratify patients based on the severity of EPI. Also, further analysis was limited because there were only 3 studies that used 72-hour fecal fat. The rest of the studies used 24-hour fecal fat.
Sensitivity Analysis for Fecal Elastase-1 Versus Secretin Stimulation Test
Various sensitivity analyses were performed as summarized in Table 3 . When the studies with subjects !18 years of age were included 9,23,26-30 the pooled sensitivity and specificity estimates were 0.75 (95% CI, 0.63-0.85) and 0.85 (95% CI, 0.70-0.93), respectively. After excluding the study by Takeda et al, 29 which was published in abstract form only, the pooled sensitivity and specificity estimates were 0.75 (95% CI, 0.54-0.88) and 0.88 (95% CI, 0.79-0.94), respectively. The pooled sensitivity and specificity estimates of studies with FE-1 cutoff value of 200 mg/g were 0.74 (95% CI, 0.53-0.87) and 0.86 (95% CI, 0.76-0.93), respectively. Lastly, in the pooled analysis of 8 studies (243 cases vs 330 controls) with CP as the cause of EPI, sensitivity and specificity were 0.73 (95% CI, 0.56-0.85) and 0.89 (95% CI, 0.79-0.95), respectively. Specifically, excluding the study by Hahn et al, 30 which included type 1 diabetes, and the study by Wali et al, 31 which included patients with failure to thrive, did not change the results.
Methodologic Quality of Included Studies
The quality of all included studies is described in Supplementary Table 7 . Most were at high risk for bias. Statistical heterogeneity was also demonstrated, I
2 value was 90.16% (95% CI, 86.19%-94.14%). Supplementary Figures 1-3 show qualitative assessment of studies with secretin stimulation tests as the control with scatter plot, chi-square plot, and Deeks funnel plot asymmetry test. There were no outliers and the Deeks funnel plot did not show significant asymmetry, all suggestive of absence of publication bias.
Qualitative assessment of studies with quantitative fecal fat as the control also did not show outliers and did not show significant asymmetry Deeks secretin stimulation test as control (P ¼ .71) and Deeks fecal fat as control (P ¼ .15).
Discussion
This is the first study in the English literature to perform a systematic review and meta-analysis of the diagnostic utility of FE-1 in EPI. Based on our review, the pooled sensitivity and specificity of FE-1 versus secretin stimulation test when all 16 studies were included was 0.77 (95% CI, 0.58-0.89) and 0.88 (95% CI, 0.78-0.93), respectively, and diagnostic accuracy was 23 (95% CI, 6-84). This diagnostic accuracy was maintained when several sensitivity analyses were performed, as shown in Table 3 .
Our study has some limitations. There was a small number of studies assessed in the final analysis of severity of EPI. Studies that used secretin stimulation test as the gold standard may have had technical variations among studies, such as protocols for collecting pancreatic juices that were not described in sufficient detail in some of the studies. Furthermore, we identified several sources of heterogeneity, including small sample sizes, study population, disease spectrum, and quality of reporting. Overall, most of the included studies used surrogate outcomes (eg, stool fat) instead of patientreported outcomes. The meta-analysis augments the indirect evidence presented by the different studies.
We performed several subgroup analyses controlling for these factors. Lastly, only 2 studies looked at sensitivity and specificity of FE-1 with cutoff value of 100 mg/g, and therefore we could not perform metaanalysis because of the small number of studies.
Our systematic review examined the utility of FE-1 for the diagnosis of EPI in pediatric and adult patients. Only 20 studies met our search criteria, which required comparison with a gold standard test, secretin stimulation test, or quantitative fecal fat estimate. The findings were heterogeneous with I 2 value of 90.16% (95% CI, 25 (218 mg/g). In terms of clinical utility, the usefulness of the test relies on the underlying prevalence of EPI in the population and the intrinsic test characteristics (FP and FN rates, sensitivity and specificity). In a low-prevalence population, such as chronic diarrhea or irritable bowel syndrome with diarrhea, FE >200 mg/g can rule out EPI with very low FN rate of 1.1%; however, FE <200 mg/g may result in overprescription of PERT because FP/TP rate is 3:1. In a high-prevalence population, such as chronic diarrhea in patients with CP or CF, FE <200 mg/g can rule in EPI with very low FP rate of 7.2%; however, FE >200 mg/g may result in higher FN rates. In this situation, a trial of PERT may be reasonable.
The pooled sensitivities of FE-1 for diagnosing mild, moderate, and severe EPI were 0.47 (95% CI, 0.29-0.70), 0.67 (95% CI, 0.25-0.92), and 0.97 (95% CI, 0.86-0.99), respectively. These estimates are similar to those reported in German by Seigmund et al 32 (abstract in English), which reported the pooled sensitivity of 0.54, 0.75 and 0.95 for mild, moderate, and severe EPI, respectively, and specificity of 0.79. Therefore, the ability of FE-1 to detect mild and moderate EPI is poor to modest, which can result in FN cases in few circumstances. FN test has the consequence of missing diagnosis of EPI, which could prevent early interventions and treatment. However, FP results, may lead to unnecessary treatment with pancreatic enzymes with possible side effects and unnecessary increase in the cost of care. Additionally, assay variability might have implications in using FE-1 test as a screening tool in patients with chronic diarrhea, because a single value may be misleading, leading to a FP diagnosis of EPI.
Based on our results, FE-1 demonstrated similar high sensitivity and specificity to diagnose severe EPI when . Most studies included in meta-analysis comprised of patients with CP (10 studies) and only few had CF (3 studies). Approximately 36% of patients with CP presented with diarrhea that lead to the diagnosis of EPI. This finding suggests that FE-1 could be used in identifying EPI in the setting of CP presenting with or without diarrhea and also possibly reducing the use of empiric therapeutic trial of pancreatic enzymes when these are not indicated.
This systematic review indicates that FE-1 is a potentially useful diagnostic tool. A normal FE-1 can rule out EPI in low pretest probability scenario (eg, patients with suspected irritable bowel syndrome with diarrhea), and abnormal FE-1 in high pretest probability scenario (eg, patients with CP) can rule in EPI; in contrast, an abnormal FE-1 in a low-pretest probability may falsely classify patients as having EPI, whereas a normal FE-1 in a high pretest probability scenario may be a FN. Larger studies are needed to further characterize the utility of this fecal biomarker and determine optimal applications in clinical practice.
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